The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Phosphorus for its at-home saliva test for Covid-19.

Developed at Phosphorus’ CLIA laboratory in New Jersey, US, the Covid-19 test uses OraSure’s Oragene ·Dx (OGD-510) saliva collection device for the detection of SARS-CoV-2 virus.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Customers can order the test through the online checkout process at the company’s website. They will be required to complete a medical questionnaire, which will be reviewed by an independent physician for approval. Once approved, the company will ship a sample collection kit to the customer’s address.

The customers will receive test results within 72 hours, accompanied by a consultation from medical personnel.

Phosphorus has partnered with IRMS Institute for Reproductive Medicine and Science at Saint Barnabas to conduct the Covid-19 testing.

The FDA emergency use approval follows a rigorous round of validation studies, in addition to the synthetic sample performance study initially required by the agency, the company noted.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, the test is the second at-home unsupervised saliva test to be approved by the FDA.

Phosphorus co-founder and CEOAlexander Bisignano said: “Covid-19 testing is essential to getting life back to normal. This test will allow people from coast to coast to be tested from the safety of their homes with the oversight of medical personnel.

“We thank the FDA for their hard work throughout this crisis and the quick action they have taken. We look forward to helping the country re-open.”

In 2017, Phosphorus introduced new genetic tests for the detection of hereditary cancers.

The company offers advanced genomic tests based on next-generation sequencing (NGS) technologies to healthcare providers and hospitals.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact